NCT01117051 2021-06-11
OIC
Takeda
Phase 3 Terminated
Clinical Trials
9 trialsNCT01696643 2018-11-15
Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3 Terminated
NCT01901302 2018-11-15
Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3 Terminated
NCT01901341 2018-11-15
The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3 Terminated
NCT01014559 2015-09-28
OXN3505
Mundipharma SAS
Phase 3 Terminated
NCT01384292 2015-06-01
Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain
AstraZeneca
Phase 3 Terminated
NCT00399659 2012-05-01
Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.
Novartis
Phase 3 Terminated
NCT00414024 2012-04-20
Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.
Novartis
Phase 3 Terminated
NCT00224692 2006-10-26
Analgesic Effect in Children of Low-Dose Ketamine for Mucositis Treated by Patient-Controlled Analgesia With Morphine
Assistance Publique - Hôpitaux de Paris
Phase 3 Terminated